Indivior (INDV) Stock Ignores Strong Q3 Earnings As Balance Sheet Risks Persist

Indivior Pharmaceuticals slipped into Q3 2026 earnings with a stock that has barely budged in the very short term, up just 0.3% today and down about 11.6% over three months. The muted move hides a punchy headline. The business just turned in quarterly revenue of US$356 million and basic earnings per share of US$1.16, both solid figures for a mid-cap specialty pharma focused on addiction and mental health treatments.

The real story sits beyond today’s small price tick. Trailing twelve month earnings now support a single digit P/E of 9.3x, while the balance sheet still carries negative equity and weak debt coverage that long term holders cannot ignore.

Love Indivior Pharmaceuticals’ single digit P/E but concerned about the fragile balance sheet? Run the stock against our list of solid balance sheet and fundamentals stocks (25 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$356 million vs. US$314 million (up about 13.4%)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$137 million vs. US$42 million (up more than 3x)
• Basic EPS (Q3 2026 vs. Q3 2025): US$1.16 vs. US$0.336 (up more than 3x)
• Products in Phase II (Q3 2026 vs. Q3 2025): 1 product vs. 2 products (pipeline at an earlier stage, reduced by 1 program)

Tired of scrolling through dense earnings reports and raw figures for Indivior Pharmaceuticals? See the whole story in a visual dashboard that brings its valuation into focus with our company report for Indivior Pharmaceuticals..

Indivior bullish platform story meets early checkpoints

Optimists argue that Indivior Pharmaceuticals plus Supernus can carry SUBLOCADE and a wider CNS portfolio for years if execution lines up.

"Bullish analysts expect Indivior Pharmaceuticals, combined with Supernus, to build a larger CNS-focused platform that can support a long run for SUBLOCADE and other products while keeping leverage around 1x."

Record Q3, SUBLOCADE net revenue up 22% year on year, and shareholder approval for the all stock merger show that cornerstone pieces are lining up. The expected November 2 closing and targeted US$125 million of annual cost synergies mark tangible progress toward the scale and efficiency this thesis leans on.

Bear case on concentration and execution still in play

Skeptics worry that Indivior Pharmaceuticals could remain too tied to SUBLOCADE and deal promises if other levers disappoint.

"If these headwinds continue beyond 2026 or offset SUBLOCADE gains, consolidated growth could stay subdued and limit the upside for net revenue and adjusted EBITDA."

Q3 delivered record results and SUBLOCADE growth, yet 2026 guidance still points to only about 1% higher total net revenue at the midpoint. That restrained outlook, alongside pressure in SUBOXONE Film, Rest of World optimization and PERSERIS runoff, means the concern about muted consolidated expansion is not cleared away by this quarter.

One Narrative disagrees with today's price. → See where this Narrative says Indivior Pharmaceuticals should trade.

Hunt Quiet Disconnects In Plain View

Indivior Pharmaceuticals just showed how a busy earnings story can sit beside a muted share price. The real opportunity is spotting stocks that could be undervalued before the market closes that gap.

• Company 1 - 21% below our estimate - uses expanded capacity to package higher value photonics modules for hyperscalers leaning into AI data centers.
• Company 2 - 38% below our estimate - adds high horsepower engine lines aimed at long term data center power contracts as capacity projects come online.
• Company 3 - 37% below our estimate - leans into heavy haul freight while rolling out AI tools that tighten carrier vetting and curb insurance and fraud costs.

Three companies from the same screener. Open the full list of 29 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com